While Novavax (NASDAQ:NVAX) missed out on the Trump administration’s Warp Speed initiative, the biotech is getting $60M to fund the manufacturing of its experimental COVID-19 vaccine from the U.S. Defense Department.
The deal includes the delivery of 10M doses of its vaccine – NVX-CoV2373 – to the DoD this year.
https://seekingalpha.com/news/3580671-novavax-scores-defense-funding-for-covidminus-19-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.